ArticlePloS one2025

Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China.

Shuo Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.